HOME JOURNALS CONTACT

International Journal of Pharmacology

Year: 2006 | Volume: 2 | Issue: 5 | Page No.: 543-548
DOI: 10.3923/ijp.2006.543.548
Effect of 3-Aminobenzamide, an Inhibitor of Poly (ADP-Ribose)Polymerase in Experimental Cardiac Hypertrophy
P. Balakumar and Manjeet Singh

Abstract: The male Wistar rats were anaesthetized with thiopentone sodium (35 mg kg-1, i.p.,) and were subjected to Partial Abdominal Aortic Constriction (PAAC) for 4 wk. 3-aminobenzamide (10, 20 mg kg-1 i.p., b.i.d) treatment was started three days before surgery and it was continued for 4 weeks after surgery. The Left Ventricular (LV) hypertrophy and LV dysfunction were assessed by measuring ratio of LV weight to body weight (LVW/BW), LV wall thickness (LVWT), LV collagen content, protein content, RNA concentration, Left Ventricular Developed Pressure (LVDP), rate of pressure development (dp/dtmax) and rate of pressure decay (dp/dtmin). Further, Venous Pressure (VP) and Mean Arterial Blood Pressure (MABP) were recorded. The PAAC produced LV hypertrophy by increasing LVW/BW, LVWT, LV protein content and LV RNA concentration. Further, PAAC was noted to produce LV dysfunction by decreasing LVDP, dp/dtmax, dp/dtmin and increasing LV collagen content. Moreover, PAAC has significantly increased VP and MABP. 3-Aminobenzamide, a PARP inhibitor markedly attenuated PAAC-induced LV hypertrophy, LV dysfunction, increase in VP and MABP. These results suggest that 3-aminobenzamide prevented PAAC-induced cardiac hypertrophy and LV dysfunction which may be due to inhibition of PARP.

Fulltext PDF Fulltext HTML

How to cite this article
P. Balakumar and Manjeet Singh, 2006. Effect of 3-Aminobenzamide, an Inhibitor of Poly (ADP-Ribose)Polymerase in Experimental Cardiac Hypertrophy. International Journal of Pharmacology, 2: 543-548.

© Science Alert. All Rights Reserved